Commonly Reported Side Effects Mild injection site irritation or redness Headache or fatigue (usually transient in early dosing) Nausea (rare, typically with higher doses or fasted use) In human trials, AOD9604 demonstrated a strong safety profile with no significant adverse effects or changes in glucose, insulin, or organ size. Heffernan et al., Journal of Endocrinology No IGF-1 Elevation or Growth Risks Unlike hGH, AOD9604 does not stimulate systemic growth meaning: No risk of acromegaly or organ hypertrophy No increase in cancer risk tied to IGF-1 elevation No suppression of natural hormone production Not a Controlled Substance AOD9604 is not scheduled or classified as a controlled substance in the U.S
The USPSTF 2024 anemia screening recommendation concluded that insufficient evidence exists to recommend routine anemia screening in asymptomatic pregnant women, reinforcing that coding anemia in pregnancy requires a confirmed provider diagnosis, not abnormal lab values alone
Little degradation (apparent t1/2 about 10 h) of DSIP to major metabolites, tryptophan (trp) and des-trp DSIP, occurred over the time of the diffusion experiments
Seeds and the SSRP Institute: Everything included in SSRP Digital Cellular Medicine Mondays Video Series Peptide World Congress Recordings Archive Grand Rounds Event Access Best Value $99.95/month $ 83.29 /month Billed annually at $999.50 Sign Up Annually Unlock our full range of Cellular Medicine provider benefits and resources
How Long Do Lidocaine Injections Last